Johnson & Johnson shares jumped 1.2% in premarket trading on Tuesday after posting a strong first quarter. Both earnings and revenue beat analyst estimates, and the company slightly raised its full-year outlook. These results reinforce the stock’s position among 2026’s top large-cap performers, with shares up about 15% year-to-date, outperforming the nearly flat S&P 500.
Adjusted earnings for the first quarter were $2.70 per share, slightly above expectations. Sales reached $24.06 billion, about $450 million above analysts’ estimates and a 10% increase from last year. The Innovative Medicine segment led with over 11% sales growth, driven by the growing oncology portfolio. Meanwhile, the medical technology division grew by 7.7%, continuing its steady role as a secondary growth driver.
The company has raised its full-year outlook, now expecting sales of $100.3 to $101.3 billion and adjusted earnings of $11.45 to $11.65 per share. These modest increases reflect management’s measured confidence in demand, tempered by caution due to the uncertain economy.
Oncology is J&J’s top growth driver, anchored by three multiple myeloma drugs: Darzalex, Tecvayli, and Carvykti. Management targets $50 billion in cancer sales by 2030. Carvykti, a CAR-T cell therapy, achieved blockbuster status in 2025, boosting segment revenues. Although Darzalex faces patent expiry in the mid-2030s, J&J’s continued oncology innovation supports long-term growth.
Beyond oncology, J&J’s psychiatric drug portfolio is a growing focal point for analysts, especially with Caplyta, a recent acquisition through the purchase of Intra-Cellular Therapies and now approved as an add-on to antidepressants. While its blockbuster potential remains uncertain, Caplyta’s early gains broaden J&J’s earnings prospects in a market with little competition. Meanwhile, J&J’s valuation remains weighed down by talc litigation, with some 74,360 talc-related lawsuits still pending after a Texas bankruptcy court rejected the latest consolidation attempt. This ongoing legal uncertainty clouds an otherwise cleaner investment outlook, making litigation developments a key variable for traders assessing risk-adjusted returns. Despite this, J&J maintains its baby powder is safe and asbestos-free.
Featured CoursesRecent news
D-Wave Stock Rises 2.7% Despite 81% Revenue Drop: Here’s Why
Despite D-Wave Quantum’s 81% revenue drop, shares rose 2.7% in premarket trading. Investors focused on a jump in bookings, indicating real business progress. Here’s a look at the numbers and why the company’s outlook matters more than its recent performance. First-quarter revenue fell to $2.86 million, down from last year and below the $4.2 million […]
GameStop Shares Drop 4.7% After eBay Turns Down $56B Takeover Offer
eBay swiftly rejected GameStop’s $56 billion takeover bid, calling it neither credible nor attractive. GameStop shares fell 4.7% in premarket trading. This decision raises questions about what it means for both companies and whether Ryan Cohen will give up or try again. Most investors were not surprised. Since the bid was announced, eBay’s stock traded […]
Hims Stock Drops 14.6% After Posting an Unexpected Loss
Hims and Hers Health’s latest results disappointed investors. Shares dropped 14.6% in premarket trading on Tuesday. The company posted a first-quarter loss, catching analysts off guard. They had expected a profit. Here’s a look at what happened, what the company’s guidance means for the future, and whether the stock’s sharp drop is justified. The subscriber […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.